The cumulative survival rates at 60 months was 18.5% and 10.8% in the OSCC patients with relatively higher and lower LC3 expression in tumor sites, respectively; this rate was 20.3% and 8.2% in those with and without areca nut usage, respectively. Here, MAP1LC3A is linked to neoplasm.